Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy, Immuno-Oncology, Amyloidosis, and Allogeneic Cell Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B2M drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | B2M Recombinant Protein (Wild-Type & D76N Mutant). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW ~11.8 kDa. Monomeric confirmation by SEC. | View B2M Products |
| Gene Delivery | B2M Lentivirus Particles. Full-length ORF for stable overexpression. CMV promoter, Puromycin marker. Concentration >1E8 TU/mL. | View B2M Products |
| Benchmark Ab | Anti-B2M Recombinant Antibody (Human IgG1 Isotype). Sequence-verified positive control for binding assay development. Endotoxin controlled. | View B2M Products |
| Validator | B2M siRNA Set (3 target-specific + 1 control). For knockdown verification and assay specificity controls. | View B2M Products |
| Related Target: HLA-A (HLA-A*02:01) | MHC I Heavy Chain. Essential for pMHC complex assembly in TCR-mimic antibody screening. Forms heterodimeric MHC I complex with B2M. | View HLA-A Products |
| Related Target: TAP1 | Antigen processing and MHC I assembly pathway; synergistic target for combination immuno-oncology strategies. | View TAP1 Products |
| Related Target: ERAP1 | Endoplasmic Reticulum Aminopeptidase 1. Peptide trimming enzyme; upstream regulator of B2M loading. | View ERAP1 Products |
| Related Target: BCMA | Synergistic target for Multiple Myeloma cell therapy and bispecifics. | View BCMA Products |
| Related Target: HLA-G | Immune checkpoint partner related to MHC class I modulation. | View HLA-G Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ubiquitous expression requires cross-species toxicology bridging (Human/Cyno/Mouse) | Human, Cyno, and Mouse B2M ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Soluble serum B2M sink vs. membrane-bound target discrimination | High-purity recombinant B2M (monomeric, endotoxin-controlled) for quantitative binding and competition assays. |
| B2M loss-of-function (LOF) resistance mutation screening | Defined B2M mutant protein panel (e.g., truncations, missense variants, D76N) for epitope retention and selectivity profiling. |
| Lack of conformation-specific controls for pMHC complex folding | HLA-B2M Complex Proteins with verified peptide binding groove integrity; HPLC purity >95%. Co-expression systems and benchmark antibody included. |
| Amyloidogenic aggregation studies (e.g., dialysis-related amyloidosis) | D76N Mutant Protein available (theoretical MW 11.8 kDa, native folding confirmed) for Thioflavin T kinetics and aggregation inhibitor screening. |
| Knockout validation in allogeneic cell therapies | Sequence-verified anti-B2M benchmark antibodies for precise flow cytometry screening of CRISPR-mediated knockout. |
| High background in serological assays & false positives | HEK293-expressed (native glycosylation/folding) antigens; validated siRNA included for strict specificity checks. |
Live B2M R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for B2M therapeutics is intensifying, with research groups advancing from proof-of-concept antibodies to next-generation modalities including ADCs, TCR-mimic molecules, and gene-edited cell therapies. Beta-2-microglobulin (B2M) is a non-covalently linked component of the MHC class I complex. As first-generation anti-B2M ADCs approach the clinic for multiple myeloma, and TCR-mimic pipelines expand, the next wave of R&D is targeting complex pMHC assembly mechanisms, aggregation inhibition for dialysis-related amyloidosis (particularly driven by the D76N mutant), and most notably, CRISPR-mediated knockout of B2M to engineer "off-the-shelf" universal T-cells for allogeneic CAR-T therapy, mitigating Graft-versus-Host Disease (GvHD). Concurrently, resistance mechanisms involving B2M loss-of-function mutations are being studied to overcome immune evasion in solid tumors. Understanding MHC I biology and epitope selection is critical for rational drug design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Editing (CRISPR) / Cell Therapy | CRISPR Therapeutics, Allogene | Hematological Malignancies | Knockout Validation (Need high-affinity Benchmark Abs for flow cytometry) |
| ADC | Emerging Biotechs, Oncology Focused | Multiple Myeloma, Lymphoma | Internalization Assay (Need high-purity monomeric B2M to avoid aggregate artifacts) |
| TCR-mimic / Bispecific Antibodies | Immunocore, AlloVir, Various early-stage R&D | Solid Tumors (pMHC targeting), Refractory Hematologic Malignancies | Heterodimer Validation (Need native-folded HLA-A2-B2M complex with specific peptides) |
| Aggregation Inhibitor (Small Molecule/Peptide) | Renal/Pfizer-focused Divisions | Dialysis-related Amyloidosis | Thioflavin T Kinetics (Need D76N Mutant vs WT comparison) |
全球研发格局 (Global R&D Landscape)
B2M (β2-微球蛋白) 在药物研发领域的地位非常独特。它不仅作为传统的靶向分子（针对多发性骨髓瘤、淋巴瘤），更是当前通用型细胞疗法 (Allogeneic CAR-T/TCR-T) 领域的绝对核心。主流应用机制包括：超过 70% 针对 B2M 的研发活动集中在基因编辑敲除（CRISPR/Cas9 或 TALEN），以 Allogene Therapeutics、CRISPR Therapeutics 为代表的头部企业通过敲除供体 T 细胞表面的 TRAC 和 B2M 基因，消除 HLA I 类分子的表达，从而避免异体移植排斥反应（GvHD）和宿主对移植物的排斥。在直接靶向疗法方面，ADC（抗体偶联药物）和单抗领域，由于 B2M 在多发性骨髓瘤 (MM) 及部分恶性血液病细胞表面高度表达，创新药企正在开发直接结合并介导内吞的 B2M 靶向药物。此外，针对 B2M D76N 突变体与透析相关淀粉样变性 (DRA) 的聚集抑制剂开发是另一重要方向。
前瞻性市场预测 (Future Forecast)
未来 3-5 年，随着自研 CAR-T 高昂的成本成为商业化瓶颈，“现货型” (Off-the-shelf) 细胞疗法将迎来爆发，B2M 相关的检测试剂需求将随之激增。同时，耐药性与免疫逃逸机制检测需求上升：部分实体瘤通过自发性 B2M 突变/缺失来下调 MHC-I 表达，从而逃避 PD-1/PD-L1 和 CD8+ T 细胞的杀伤。针对 B2M 缺失的肿瘤模型建立以及相关旁路途径的药物联用（如与 NK 细胞激活剂联用）将成为重要研发方向。新一代 ADC 靶点挖掘中，B2M 由于在特定血癌细胞表面高更新率，可能作为 ADC 的潜在载体，但其在全身有核细胞的广泛表达要求抗体设计具备极高的肿瘤微环境选择性（例如 pH 敏感型抗体或前药设计）。
分子差异化需求与 Assay 策略 (Molecular Differentiation & Assay Strategy)
为了在 B2M 相关管线中脱颖而出，药企在早期筛选阶段必须克服核心挑战并执行严格的 Assay 策略。对于直接靶向 B2M 的 ADC 或单抗，需要区分游离态 B2M 与结合态 B2M (MHC-I 复合体)；对于基因敲除验证，抗体需具备极高亲和力以捕捉微量残留表达。内吞效率是 ADC 管线的关键：基于 pH 敏感荧光染料的内吞测定和体外细胞毒性实验可验证快速内化和溶酶体释放。安全性方面，由于所有有核细胞均表达 B2M，需要验证候选药物在正常组织上的结合率，通过高浓度稳定性测试和跨物种交叉反应谱筛选。TarMart 提供 HEK293 系统表达、天然糖基化修饰、纯度 >95% 且内毒素严格控制的重组 B2M 蛋白，以及 Sequence Verified 的基准抗体、慢病毒和 siRNA 构建方案，完美契合上述 Assay 需求。
关联靶点推荐 (Cross-Selling Strategy)
在开发 B2M 相关药物特别是通用型细胞疗法或多发性骨髓瘤管线时，以下靶点具有协同开发与联用价值：BCMA（多发性骨髓瘤经典靶点）、HLA-G/HLA-E（B2M 敲除后抑制 NK 细胞 “Missing Self” 机制的策略）、CD19（通用型 CAR-T 的经典验证靶标）、以及 TAP1/ERAP1（抗原加工与呈递通路上游调控因子）。